Patents by Inventor Paul S. Watson

Paul S. Watson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Non-nucleotide composition and method for inhibiting platelet aggregation
    Patent number: 7592445
    Abstract: This invention is directed to compounds of Formulae III and V, useful for treating diseases or conditions associated with platelet aggregation.
    Type: Grant
    Filed: January 4, 2008
    Date of Patent: September 22, 2009
    Assignee: Inspire Pharmaceuticals, Inc.
    Inventors: Robert Plourde, Jr., Sammy R. Shaver, James G. Douglass, III, Paul S. Watson, José L. Boyer, Chi Tu, Melwyn A. Abreo, Lorenzo J. Alfaro-Lopez, Yangbo Feng, Daniel F. Harvey, Tatyana V. Khasonova
  • Orally bioavailable compounds and methods for inhibiting platelet aggregation
    Patent number: 7504497
    Abstract: This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or related disorders. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a non-nucleotide compound, preferably a P2Y12 receptor antagonist compound, wherein said amount is effective to inhibit platelet aggregation. The compounds useful for this invention include compounds of general Formulae III, IIIa, and IIIb, or salts, hydrates, and solvates thereof. The present invention also provides novel compounds of Formulae IIIa and IIIb, which are potent and have a good oral bioavailability.
    Type: Grant
    Filed: November 9, 2006
    Date of Patent: March 17, 2009
    Assignee: Inspire Pharmaceuticals, Inc.
    Inventors: James G. Douglass, III, Paul S. Watson, Carl A. Samuelson, Christopher S. Crean
  • PROCESS FOR THE PREPARATION OF 3,4-DISUBSTITUTED-THIAZOLIDIN-2-ONES
    Publication number: 20080287683
    Abstract: The present invention is directed to practical high-yielding synthetic processes for preparing 3,4-disubstituted-thiazolidin-2-ones, which do not compromise the absolute stereochemical integrity of the compounds. The present invention is also directed to novel compounds of 3,4-disubstituted-thiazolidin-2-ones. The compounds prepared by the present invention are useful in the synthesis and manufacture of compounds (such as latrunculins and/or their analogs) for treating diseases or conditions associated with inhibiting actin polymerization.
    Type: Application
    Filed: July 30, 2008
    Publication date: November 20, 2008
    Inventors: Jonathan B. DeCamp, Paul S. Watson, Jin She
  • CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE
    Publication number: 20080214614
    Abstract: The present invention is directed to synthetic cytoskeletal active compounds that are inhibitors of rho-associated protein kinase. The present invention is also directed to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The invention is additionally directed to a method of preventing or treating diseases or conditions associated with cytoskeletal reorganization. In one embodiment of the invention, the method treats increased intraocular pressure, such as primary open-angle glaucoma. The method comprises administering to a subject a therapeutically effective amount of a cytoskeletal active compound of Formula I or Formula II, wherein said amount is effective to influence the actomyosin interactions, for example by leading to cellular relaxation and alterations in cell-substratum adhesions.
    Type: Application
    Filed: December 17, 2007
    Publication date: September 4, 2008
    Inventors: John W. Lampe, Paul S. Watson, David J. Slade, Ward M. Peterson, Christopher S. Crean, Jason L. Vittitow, Jonathan Bryan DeCamp, Nicholas F. Pelz
  • Process for the preparation of 3,4-disubstituted-thiazolidin-2-ones
    Patent number: 7414137
    Abstract: The present invention is directed to practical high-yielding synthetic processes for preparing 3,4-disubstituted-thiazolidin-2-ones, which do not compromise the absolute stereochemical integrity of the compounds. The present invention is also directed to novel compounds of 3,4-disubstituted-thiazolidin-2-ones. The compounds prepared by the present invention are useful in the synthesis and manufacture of compounds (such as latrunculins and/or their analogs) for treating diseases or conditions associated with inhibiting actin polymerization.
    Type: Grant
    Filed: March 22, 2007
    Date of Patent: August 19, 2008
    Assignee: Inspire Pharmaceuticals, Inc.
    Inventors: Jonathan B. DeCamp, Paul S. Watson, Jin She
  • Non-nucleotide composition and method for inhibiting platelet aggregation
    Patent number: 7335648
    Abstract: This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or related disorders. The method comprises administering to a compounds useful for this invention include compounds of general Formulae I and III-XII, or salts, hydrates, and solvates thereof. The present invention also provides novel compounds of Formulae I and III-XII.
    Type: Grant
    Filed: May 5, 2005
    Date of Patent: February 26, 2008
    Assignee: Inspire Pharmaceuticals, Inc.
    Inventors: Robert Plourde, Jr., Sammy R. Shaver, James G. Douglass, III, Paul S. Watson, José L. Boyer, Chi Tu, Melwyn A. Abreo, Lorenzo J. Alfaro-Lopez, Yangbo Feng, Daniel F. Harvey, Tatyana V. Khasonova
  • Cytoskeletal active compounds, compositions and use
    Patent number: 7320974
    Abstract: The present invention is directed to synthetic cytoskeletal active compounds that are related to natural Latrunculin A or Latrunculin B. The present invention is also directed to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The invention is additionally directed to a method of preventing or treating diseases or conditions associated with actin polymerization. In one embodiment of the invention, the method treats increased intraocular pressure, such as primary open-angle glaucoma. The method comprises administering to a subject a therapeutically effective amount of a cytoskeletal active compound of Formula I or II, wherein said amount is effective to influence the cytoskeleton, for example by inhibiting actin polymerization.
    Type: Grant
    Filed: March 23, 2006
    Date of Patent: January 22, 2008
    Assignee: Inspire Pharmaceuticals, Inc.
    Inventors: John W. Lampe, Robert Plourde, Jr., Jin She, Jason L. Vittitow, Paul S. Watson, Michael T. Crimmins, David J. Slade
  • PROCESS FOR THE PREPARATION OF 3,4-DISUBSTITUTED-THIAZOLIDIN-2-ONES
    Publication number: 20070225504
    Abstract: The present invention is directed to practical high-yielding synthetic processes for preparing 3,4-disubstituted-thiazolidin-2-ones, which do not compromise the absolute stereochemical integrity of the compounds. The present invention is also directed to novel compounds of 3,4-disubstituted-thiazolidin-2-ones. The compounds prepared by the present invention are useful in the synthesis and manufacture of compounds (such as latrunculins and/or their analogs) for treating diseases or conditions associated with inhibiting actin polymerization.
    Type: Application
    Filed: March 22, 2007
    Publication date: September 27, 2007
    Inventors: Jonathan B. DeCamp, Paul S. Watson, Jin She
  • N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
    Patent number: 6906066
    Abstract: The present application describes modulators of CCR3 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.
    Type: Grant
    Filed: June 19, 2003
    Date of Patent: June 14, 2005
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Soo S. Ko, George V. Delucca, John V. Duncia, Joseph B. Santella, III, Dean A. Wacker, Paul S. Watson, Jeffrey G. Varnes, Wenqing Yao
  • 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity
    Patent number: 6706735
    Abstract: The present application describes modulators of CCR3 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.
    Type: Grant
    Filed: June 26, 2002
    Date of Patent: March 16, 2004
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Paul S. Watson, Soo S. Ko, George V. DeLucca, John V. Duncia, Joseph B. Santella, III, Dean A. Wacker
  • 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity
    Publication number: 20030144273
    Abstract: The present application describes modulators of CCR3 of formula (I): 1
    Type: Application
    Filed: June 26, 2002
    Publication date: July 31, 2003
    Inventors: Paul S. Watson, Soo S. Ko, George V. DeLucca, John V. Duncia, Joseph B. Santella, Dean A. Wacker
  • 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity
    Patent number: 6441001
    Abstract: The present application describes modulators of CCR3 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.
    Type: Grant
    Filed: December 17, 1999
    Date of Patent: August 27, 2002
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Paul S. Watson, Soo S. Ko, George V. Delucca, Joseph B. Santella, III, Dean A. Wacker, John V. Duncia